1 min read
Meet Veristat at BIO-Europe Spring: March 23-25, 2026 - Lisbon, Portugal
🔬 Connecting with the Global Biopharma Community
Veristat is pleased to attend BIO-Europe Spring, where biotech...
1 min read
Based on an online seminar presentation made in collaboration with TOPRA and Veristat, this article dives into the future of the European medicines and medical devices industry and the changes in legislation that are being prompted by the evolving pharmaceutical environment. 
On 25 November 2020, the European Commission (EC) adopted the patient-centric New Pharmaceutical Strategy for Europe and published its roadmap for the revision of the general pharmaceutical legislation in 2021. The European Commission has begun initiating work in several areas, including the pediatric and orphan review.
In this article, you will get a comprehensive overview of the following:
- Unmet medical needs and how the New Pharmaceutical Strategy aims to prioritize them.
- Changes in the Orphan and Pediatric legislation review.
- The European Commission’s plans for ensuring the accessibility and affordability of medicines in all member states.
- Future objectives for innovation and digital transformation in the European pharmaceutical industry.
- New pharmaceutical strategy for Europe looking forward.
Read the full article to learn more: https://www.regulatoryrapporteur.org/european-medicines-and-medical-devices-future-trends/222.article